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KAJIAN REAKTIVITI VASKULAR, PROFIL KIMIA, TOKSIKOLOGI DAN 
FARMAKOKINETIK EKSTRAK ANDROGRAPHIS PANICULATA (NEES.) 
 
ABSTRAK 
Tujuan kajian ini adalah untuk menilai reaktiviti vaskular, profil kimia, 
ketoksikan dan farmakokinetik ekstrak Andrographis paniculata. Ekstrak kloroform 
Andrographis Paniculata (APCE) didapati memberikan kesan vasorelaksasi poten 
keatas kontraksi aruhan norepinefrin (NE) pada aorta toraks tikus. Analisis HPLC 
dan 1H-NMR APCE menunjukan kehadiran andrografolida (ANG), 14-
deoksiandrografolida (DA) dan 14-deoksi-11,12-didehidrografolida (DDA). Rawatan 
kronik selama 4 minggu dengan APCE 25, 50 dan 100 mg/kg/hari pada tikus 
hipertensif spontan (SHR) menunjukkan peningkatan relaksasi tergantung-
endotelium dan tidak tergantung-endotelium terhadap asetilkolina (ACh) dan natrium 
nitroprusida (SNP) mungkin kerana pengaktifan nitrik oksida (NO) sintase dan juga 
perangsangan pengeluaran NO dalam sel-sel endotelium yang membawa kepada 
perencatan bagi lintasan kontraksi aruhan-Ca2+. Penurunan tekanan darah sistole 
(SBP) secara signifikan (p<0.001) mungkin disebabkan oleh tindakan vasodilatasi 
pada saluran darah.  
 
APCE, sub-fraksi AP (AP1), DA dan DDA bergantung dos merencat kedua-
dua kontraksi tonik aruhan-NE dan kontraksi aruhan-K+ berkepekatan tinggi 
(80mM), mencadangkan yang APCE, AP1, DA dan DDA bertindak sebagai 
penghalang saluran Ca2+ kepada kedua-dua saluran kendalian reseptor dan saluran 
tergantung potensi. DA, DDA dan APCE juga merencat kontraksi fasik aruahan-NE 
menyarankan yang DA, DDA dan APCE merencat pembebasan Ca2+ daripada 
 xxvi
retikulum sarkoplasma. Pengurangan kepekatan Ca2+ yang menyumbang kepada 
vasorelaksasi yang diaruhkan oleh DA, DDA dan APCE berkemungkinan melalui 
perencatan influks Ca2+ dan perencatan pembebasan Ca2+ dalam sel. Kesan 
perencatan DA, DDA dan APCE keatas kontrakasi fasik aruhan dos rendah NE 
mungkin bertindak melalui perencatan influks Ca2+ melalui lintasan bebas kalsium.  
 
Akhirnya kajian ketoksikan akut dan ketoksikan kronik APCE 100, 300, 
1,000 dan 2,000 mg/kg/hari tidak menunjukan tanda-tanda ketoksikan sehingga ke 
akhir 28 hari jangkamasa penyelidikan. Tiada perubahan peningkatan berat badan 
mingguan dan profil hematologi serta perubahan profil makroskopik dan 
histopatologi organ dalaman semasa postmortem. Oleh itu, keputusan yang 
diperolehi mencadangkan yang APCE adalah tidak toksik sehingga 2,000 mg/kg. 
Dalam kajian farmakokinetik APCE menggunakan ANG dan DDA sebagai penanda 
menunjukkan farmakokinetik tak linear pada dos 1,000 mg/kg pada tikus.   
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VASCULAR REACTIVITY, CHEMICAL PROFILE, TOXICOLOGICAL 
AND PHARMACOKINETIC STUDIES OF ANDROGRAPHIS PANICULATA 
NEES. EXTRACTS 
 
ABSTRACT 
 
The aims of the study were to evaluate the vascular reactivity, chemical 
profile, toxicity and pharmacokinetic of Andrographis paniculata (AP) extracts. 
Andrographis paniculata chloroform extract (APCE) was found to be a potent 
vasorelaxant against norepinephrine (NE)-induced contraction of rat thoracic aorta. 
The HPLC and 1H-NMR analysis of APCE revealed the presence of andrographolide 
(ANG), 14-deoxyandrographolide (DA) and 14-deoxy-11, 12-
didehydroandrographolide (DDA). Chronic treatment for four weeks of APCE 25, 50 
and 100 mg/kg/day in spontaneously hypertensive rats (SHR) demonstrated that it 
enhances the endothelium-dependent and endothelium-independent relaxation to 
acetylcholine (ACh) and sodium nitroprusside (SNP) presumably due to the 
activation of nitric oxide (NO) synthase and stimulation of the NO production in 
endothelial cells which lead to inhibition of Ca2+-induced contraction pathway. The 
systolic blood pressure (SBP) of SHR was significantly (p<0.001) reduced 
presumably due to its vasodilatory action on blood vessels.  
 
APCE, sub-fraction of AP (AP1), DA and DDA dose dependently inhibited 
both the NE-induced tonic contraction and high K+ (80 mM)-induced contraction, 
suggesting that APCE, AP1, DA and DDA act as a Ca2+ channel blocker of both 
receptor-operated and potential-dependent channels. DA, DDA and APCE also dose 
dependently inhibited the NE-induced phasic contraction, suggesting that DA, DDA 
and APCE inhibits the Ca2+ release from sarcoplasmic reticulum. The reduction in 
 xxviii
intracellular Ca2+ concentration that contribute to vasorelaxation induced by DA, 
DDA and APCE may be through inhibition of Ca2+ influx and inhibitions of 
intracellular calcium released. The inhibitory effect of DA, DDA and APCE on 
lower dose of NE-induced phasic contraction may act by inhibiting calcium influx 
through calcium-independent pathway.  
 
Finally the acute and chronic toxicity studies of APCE at 100, 300, 1000 and 
2000 mg/kg/day showed there was no visible sign of toxicity until the end of the 28 
days study period. There were no significant changes observed on the weekly body 
weight gain and hematological profile as well as macroscopic and histopathological 
profile of the internal organs on post mortem. Therefore, the results obtained suggest 
that APCE is nontoxic up to 2000 mg/kg body weight. In pharmacokinetic study of 
APCE using ANG and DDA as markers showed non-linear pharmacokinetics at a 
dose 1000 mg/kg in rats.  
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CHAPTER 1 
INTRODUCTION 
1.0 Introduction 
In the treatment of cardiac diseases several synthetic, semi-synthetic and         
natural drug molecules have been used from the past decades. Among the series of 
emerging drug candidates, few of active principles were also isolated from the 
natural flora and have been tested and used in various conditions of cardiovascular 
malfunctions. The physiology and etiology of cardiovascular tissues are important 
in the screening and development of new drug candidates. 
1.1 Vascular smooth muscle 
The etiology of cardiovascular disease depends on the structural integrity and 
health of the blood vessels of the cardiovascular system. The wall of an artery 
consist of three distinct layers namely tunica intima, tunica media and tunica 
adventitia. Tunica intima, the inner most layer of the artery wall, consists of a single 
layer of endothelial cells and connective tissue. The amorphous mucopolysacharide 
ground substance containing elastin, collagen, and vascular smooth muscle cells is 
referred to as the tunica media layer. Tunica adventitia is the outermost layer 
surrounding the two inner layers and consists of strong fibrous tissue which 
maintains the shape of the vessel (Figure 1.1). Vascular smooth muscle is innervated 
primarily by the sympathetic nervous system through adrenergic receptors 
(adrenoceptors). Three types of adrenoceptors are present within vascular smooth 
muscle cells: alpha 1 (α1), alpha 2 (α2) and beta 2 (β2). Norepinephrine is the main 
endogenous agonist for adrenoceptors. 
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Figure 1.1.  Structure of artery and vein (Martini & Bartholomew, 2008). 
 
1.2 Contraction of blood vessels 
Smooth muscle contraction and the regulation of the contractile process has 
been the subject of intense studies for many years. Smooth muscle contraction is 
mainly composed of interlocked filaments held in place by a lattice work of fibres of 
dense bodies. The main contractile filaments are referred to as thick (contains 
myosin) and thin filaments (contains actin) owing to their microscopic appearance. 
Contraction occurs when these filaments slide over one another. This movement is 
mediated by the process of cross-bridge cycling. Variations in the free cytosolic 
calcium (Ca2+) concentrations in vascular smooth muscle cells have been identified 
as the primary regulatory signal for smooth muscle contractions. The Ca2+ 
concentration in resting smooth muscle ranges between 80 to 270 mM while 
increase in the Ca2+ concentrations to 500 mM  to 700 mM results in contraction 
(Webb, 2003).  
 3
Figure 1.2 (A) shows the presence of muscarinic (M2) and muscarinic (M3) 
receptors in most smooth muscle cells. Activation of M3 receptors elicit contraction 
through stimulation of phospholipase C-β (PLC-β), which cleaves 
phosphatidylinositol-4, 5-bisphosphate into diacylglycerol (DAG) and inositol-1, 4, 
5-trisphosphate (IP3). The IP3 mobilizes Ca2+ and triggers contraction. Beta (β)-
adrenergic receptor activation stimulates adenylyl cyclase (AC) to generate cyclic 
adenosine-mono-phosphate (cAMP), which causes the relaxation of smooth muscle. 
M2 receptors inhibit AC to prevent the relaxation effect on stimulation of the β-
adrenergic receptor. 
 
Figure 1.2 (B) illustrates that most peripheral blood vessels contain M3 
receptors on the endothelium, which trigger the synthesis of nitric oxide. Nitric 
oxide (NO) diffuses into the smooth muscle, where it mediates relaxation through 
the production of cyclic guanosine monophosphate (cGMP). 
 
  Figure 1.2 (C) shows the activation of M1 receptors and nicotinic receptors (N) 
in parasympathetic ganglia causing the release of an inhibitory neurotransmitter (IN) 
from postganglionic neurons in gastrointestinal sphincters. This inhibitory 
neurotransmitter is usually adenosine triphosphate (ATP), NO or vasoactive 
intestinal peptide (VIP) and causes the sphincter smooth muscle to relax. 
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Figure 1.2. Receptor-mediated contraction and relaxation in different types of           
                   smooth muscle (Mineman and Wecker, 2004). 
 
 
Vasoconstricting neurotransmitters and hormones bind to their receptors on 
the cell surface and initiate a series of processes leading to the contraction of 
vascular smooth muscle. Most receptors activate various types of guanosine 5-
triphosphate (GTP) binding proteins (G-proteins), which are coupled to different ion 
channels and enzymes, and modulate their activities. These enzymes include both 
phospholipase C (PLC), which metabolises inositol diphosphate (IP2) to produce 
inositol triphosphate (IP3), diacylglycerol (DAG). Adenylate cyclase metabolises 
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ATP to produce cAMP. IP3 releases Ca2+ from intracellular stores whereas DAG 
activates protein kinase C (PKC), which phosphorylates a number of proteins. In 
addition to the activation of the IP3 metabolism, vasoconstrictors such as 
norepinephrine have been shown to depolarize the smooth muscle cells and 
consequently activate voltage operated Ca2+ channels in the plasma membrane of the 
smooth muscle, leading to an increased influx of extra cellular Ca2+. Moreover, the 
existence of receptor operated Ca2+ channels have been proposed in smooth muscle 
cells (Webb, 2003). The activation of this mechanism increases intracellular Ca2+, 
which is the primary signal for smooth muscle contraction (Bolton, 1979; Karaki et 
al., 1984; Allen & Walsh, 1994). As a consequence of elevated intracellular Ca2+ 
concentration, Ca2+ binds to calmodulin to form Ca2+- calmodulin complex, which 
removes the auto inhibition of myosin light chain kinase (MLCK). The activated 
MLCK phosphorylates reversibly the light chain of myosin and activates the myosin 
ATPase. The phosphorylated myosin cyclically binds to actin filaments producing 
force or the shortening of the smooth muscle (Figure 1.3). The contractile force does 
not, however, depend directly on intracellular Ca2+, since the contractile force may 
be enhanced by increasing the responsiveness of the contractile machinery or the 
sensitivity of the myofilaments to intracellular Ca2+ (Webb, 2003). These 
modulatory mechanisms for changing the Ca2+ metabolism, serve an important role 
in the regulation of vascular smooth muscle tone (Somlyo et al., 1999; Webb, 2003).  
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Figure 1.3. Mechanisms of contraction of vascular smooth muscle cells (Mineman   
and Wecker, 2004). 
  
1.3 Smooth muscle relaxation 
Relaxation of smooth muscle requires a fall in intracellular Ca2+ levels to 
resting levels and dephosphorylation of myosin. Smooth muscle relaxation occurs 
either as a result of removal of the contractile stimulus or by direct action of a 
substance that stimulates the inhibition of the contractile mechanism. This process is 
catalyzed by a specific myosin light chain phosphatase (MLCP) (Somlyo et al., 
1999). Alterations in the mechanisms that lead to reduction in intracellular Ca2+ 
levels and/or increase in MLCP activity may contribute to alterations in 
responsiveness of smooth muscle cells. Several mechanisms have been implicated in 
the sequestration or removal of cytosolic Ca2+. For an instance, the inhibition of 
sarcoplasmic reticular Ca2+ and Mg2+-ATPase activity which mediates the release of 
intracellular Ca2+ leads to reduction in cytosolic Ca2+ concentrations and hence 
causes relaxation of smooth muscle cells (Webb, 2003). In addition, the inhibition of 
receptor-operated and voltage-operated Ca2+ channels located in the plasma 
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membrane which are important in the Ca2+ influx and smooth muscle contraction, 
leads to the reduction in intracellular Ca2+ concentrations and hence causes smooth 
muscle relaxation (Webb, 2003). 
 
1.4 Endothelium 
1.4.1 Physiology of endothelium 
 The vascular endothelium is the largest endocrine organ in the body. It is 
approximately 14,000 square feet in surface area with a size of 6.5 tennis courts in 
area and five times the heart size in mass with a total weight of about 2 kg (Amudha 
et al., 2002). The vascular endothelium under normal, healthy physiological 
conditions forms a continuous sheet of organized monolayer polyhedral cells. The 
endothelial cells are tightly interlocked so that passage of products from the blood 
occurs through the endothelial cell. These cells are both a passive filter and a 
metabolically active organ that synthesizes and release several vasoactive substances 
into the blood and into the underlying vascular smooth muscle cells, which regulates 
the vascular homeostasis.  
 
The endothelium-derived vasoactive substances include vasodilators, such as 
NO, prostacyclin and yet unidentified endothelium-derived hyperpolarizing factor 
and also vasoconstrictors, such as free radicals, cyclooxygenase products and 
endothelin-I. Endothelium-derived vasoactive substances alter the vascular tone of 
the artery through myogenic mechanisms, local hormones or chemical substances, 
and/or metabolic by-products. Consequently, signal transmission causes muscle 
contraction or muscle relaxation and can occur through numerous pathways 
involving nerve signals, blood borne substances and locally generated substances. 
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For example, endothelium-derived vasoconstrictors typically bind to receptors on the 
smooth muscle cells and can elicit a contraction through enhancing intracellular Ca2+ 
concentrations. On the other hand, endothelium-derived vasodilators act in several 
ways to protect the integrity of the artery, chief among which are induction of 
vascular smooth muscle cell relaxation, inhibition of vascular smooth muscle cell 
growth, inhibition of platelet aggregation and thrombosis and inhibition of monocyte 
adhesion.  
 
             1.5 Endothelium and cardiovascular disease 
Endothelial cells produce several biologically active substances that play key 
role in local regulation of blood flow, blood pressure and vascular tone (Furchgott & 
Vanhoutte, 1989; Luscher et al., 1995; Gewaltig et al., 2002; Endemann & Schiffrin, 
2004). It is not surprising that alterations in physiological functions of endothelial 
cells have the potential to contribute directly to the impaired vascular homeostasis 
and hence to pathogenesis of cardiovascular disease. In support of this hypothesis, 
data from clinical and experimental studies have demonstrated that impairment of 
endothelial function either initiates or associates with the development and 
progression of cardiovascular disease (Endemann & Schiffrin, 2004). Endothelial 
dysfunction can be determined by the reduction in the activity of endothelium-
derived vasodilators, mainly NO by local increases in antagonists (endothelium-
derived contractile factors) to these vasodilators, or by other associates of these two 
factors. On the other hand, considerable evidence suggests that the manifestation of 
endothelial dysfunction occur before the development of cardiovascular disease 
(CVD) and endothelial function has been reported to be impaired even in the 
offspring of CVD parents (Taddei et al., 1992; Taddei et al., 1996; Amudha et al., 
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2002). This shows that the onset of endothelial dysfunction may be an important 
pathogenic event preceding the development of clinically evident vascular disease. 
 
Over the last decade, extensive research has focused on determining the 
presence and nature of endothelial dysfunction in experimental models of CVD and 
in patients with CVD (Amudha et al., 2002). Investigations into the mechanisms of 
endothelial dysfunction both in hypertension and diabetes mellitus have 
demonstrated that reduced bioactivity and/or bioavailability of endothelium-derived 
nitric oxide plays an important role (Luscher & Noll, 1995; Endemann & Schiffrin, 
2004). Several factors including low-density lipoprotein (LDL) cholesterol oxidation, 
increased production of reactive oxygen species (ROS) and decreased production of 
nitric oxide via endothelial nitric oxide synthase (eNOS) have been identified as 
important etiological factors in the reduced bioavailability and/or bioactivity of 
endothelium-derived nitric oxide and subsequently, in the development of 
endothelial dysfunction (Amudha et al., 2002; Endemann & Schiffrin, 2004; 
Kalinowski & Malinski, 2004; Forestermann, 2005). An important implication of the 
free radical-oxidative stress hypothesis of endothelial dysfunction is that a wide 
range of antioxidants, including ascorbic acid and α-tocopherol, may inhibit ROS 
and reestablish endothelial function (Taddie et al., 1998; Endemann & Schiffrin, 
2004). Up to date most interventions attempting to improve endothelial dysfunction 
have targeted one or more of the numerous risk factors that can cause endothelial 
damage (Amudha et al., 2002).  
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Many pharmacological agents have been suggested to achieve vascular 
protection through various mechanisms such as reduction in the blood pressure, 
inhibition of hyperglycemia and reduction in oxidative stress. Beneficial changes to 
the endothelium from these interventions might result from promotion of vascular 
relaxation, inhibition of vasoconstriction, reduction in the production of free radicals 
or other mechanisms that protect the endothelium from injury (Amudha et al., 2002). 
The plants showing nitric oxide production can be a promising cadidates for 
vasorelaxation, which may have potential lead molecule for preventing and treating 
cardiovascular diseases such as hypertension and atherosclerosis (Park et al., 2009). 
 
1.6 Vascular mediators from the endothelium: Endothelium-derived relaxant 
factors (EDRF) 
The discovery of endothelium-derived relaxing factor and its identification as 
nitric oxide, a highly reactive free radical gas, is one of the most exiting discoveries 
of biomedical research in the last two decades (Furchgott & Zawadzki, 1980; Plamer 
et al., 1987). Over the past few years, NO has become established as a universal 
intercellular messenger that serves a variety of biomodulatory functions in 
physiological as well as pathological conditions. NO is synthesized from L-arginine 
by the enzymatic action of nitric oxide synthase (NOS), i.e., endothelial, neuronal 
and inducible, exist in mammalian cells. The endothelial subtype accounts for the 
majority of the basal and stimulated NO synthesis in endothelial cells throughout the 
vasculature (Figure 1.4). The average half-life of NO in tissue is about 3 to 6 
seconds whereas in blood it is 1 to 2 seconds. 
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The synthesis of NO can be stimulated by an increase in endothelial Ca2+ 
concentration following physical and chemical stimuli such as shear stress and 
hypoxia, activation of cell surface receptors by a variety of endogenous substances 
like acetylcholine (ACh) and bradykinin, or application of Ca2+ channel agonists 
(Vanhoutte et al., 1995; Luscher & Noll, 1995; Hansen & Nedergaard, 1999). After 
endothelial NOS is turned on by Ca2+ flux, its biosynthesizes NO in bursts for about 
a minute and it is turned off by phospharylation. On the other hand, it has also been 
(Schulz & Triggle, 1994) reported that there is a continuous and spontaneous basal 
release of NO from the endothelium, the amount of which regulates the arterial tone. 
Thus, impaired mechanism and/or inhibition of the NO production from 
endothelium causes dramatic decrease in blood flow and can certainly induce 
profound and sustained hypertension. This view is supported by the findings that 
chronic inhibition of NOS activity leads to a present of hypertension in experimental 
animals (Pechanova et al., 2004).  
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Figure 1.4. Biosynthesis of L-Arginine – Nitricoxide (NO) pathway. 
 
 
It has been suggested that there is a diminished basal NO synthesis in the 
vasculature of patients with hypertension and diabetes as well as in experimental 
hypertension and diabetes (Endemann & Schiffrin, 2004). On the other hand, 
considerable number of studies suggests that the synthesis and release of NO is 
unaffected or it may even be enhanced, but excessive production of super oxide 
anions leads to increased incapacitation of NO and subsequently, attenuates 
endothelium-dependent vasodilatation in hypertensive and diabetic arteries (Tschudi 
et al., 1996; Maffei et al., 2002). In this perspective, it is suggested that other than 
synthesis/release of NO, activation of eNOS may also lead to release of superoxide 
anions in higher quantities in hypertensive and diabetic arteries (Milstein & Katuski, 
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1999; Forstermann, 2005). In physiological conditions, the concentration of super 
oxide radicals remains low within the organism as a result of its reaction with super 
oxide dismutase (SOD) enzyme. However, in hypertension and diabetes mellitus, 
there may be an increase in the production of these radicals or deficiency of SOD 
(Gewaltig & Kodja, 2002; Endemann & Schiffrin, 2004). 
 
NO plays different roles depending on the site of its production. NO 
synthesized by eNOS diffuses out in all directions. About 10% to 30% of NO 
diffuses to the wall of blood vessels and triggers a cascade of events leading to 
smooth muscle relaxation. NO relaxes vascular smooth muscle via the activation of 
soluble guanylate cyclase that converts guanosine monophosphate (GMP) to cyclic 
GMP (Moncada et al., 1991; Hansen & Nedergaard, 1999). In smooth muscle cells, 
cGMP has been reported to activate the cGMP-dependent protein kinase that 
regulates several pathways involved in Ca2+  homeostasis with the end result being a 
reduction in the concentration of intracellular Ca2+ available for contraction and a 
decrease in the sensitivity of contractile proteins to Ca2+  (Moncada & Higgs, 1993; 
Hansen & Nedergaard, 1999). In addition, NO has been reported to hyperpolarize 
vascular smooth muscle via cGMP-dependent mechanisms as well as directly 
activating Ca2+ activated K+  channels (Kca) and Na+/K+ adenosine 5’-triphosphate 
(ATPase) activity (Gupta et al.,  1994; Cohen et al., 1995).  
 
1.6.1 Prostacyclin 
Prostacyclin (PGI2) is the major relaxant prostanoid produced by the vascular 
endothelial cells. The formation of PGs begins with the liberation of arachidonic 
acid from cell membrane phospholipids by phospholipase A2. Arachidonic acid is 
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then converted into PGG2 and PGH2 by the enzyme cyclooxygenase (COX). Finally, 
PGH2 is converted to PGI2 by the action of PGI2 synthase (Gryglewski, 1995). 
Although other PGs (PGE2, PGF2α and PGD2) are also synthesized in the endothelial 
cells, PGI2 is the major vasodilator prostanoid in all the vascular cells. 
Physiologically, PGI2 is a local rather than circulating hormone, because its blood 
levels are too low to have any general effects. The production of PGs can be blocked 
by non-steroidal anti-inflammatory drugs, such as indomethacin and aspirin, which 
inhibit both isoforms i.e. COX 1 & COX 2 - activity (Akpaffiong & Taylor, 1998; 
Nascimento et al., 2003). Recently another catalytically active COX variant, COX-3, 
derived from an alternative splicing of the COX-1 gene, has been identified in the 
brain (Chandrasekharan et al., 2002). 
 
Endothelial cells release PGI2 in response to shear stress, hypoxia, and 
stimulation of various receptors on endothelial membrane (Luscher & Noll, 1995). 
Moreover, it is suggested from in vitro experiments that NO activates PGI2 synthesis 
by activation of prostaglandin-H synthase and possibly by increasing 
cyclooxygenase activity by a cGMP-independent pathway (Gryglewski, 1995). PGI2 
exerts its vasodilatory actions by binding to membrane receptors on the smooth 
muscle, which activate adenylate cyclase and subsequently increase the intracellular 
concentration of cAMP. The elevation of intracellular cAMP leads to the reduction 
of intracellular Ca2+ concentration and to decrease in the sensitivity of contractile 
proteins to Ca2+ (Cohen & Vanhoutte, 1995). When compared with the inhibition of 
eNOS, the blockade of COX has negligible impact on blood pressure. On the other 
hand, the inhibition of COX has been found to enhance endothelium-mediated 
vasodilatation in hypertensive and diabetic rat arteries (Taddei et al., 1997; 
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Akpaffiong & Taylor, 1998; Nascimento et al., 2003). Therefore, hypertension and 
diabetes appear to be associated with an imbalance in endothelial production of 
COX-derived vasodilator and vasoconstrictor factors (figure 1.5). 
 
 
Figure 1.5. Biosynthesis of prostaglandins, lipoxygenase and cytochrome P- 450        
pathway. 
 
1.6.2 Endothelium-derived hyperpolarizing factor (EDHF)  
Defined as a group of yet unidentified substances which produce vascular 
smooth muscle hyperpolarization and relaxation. The nature of the responses 
attributed to EDHF is still unresolved, but the evidence from several sources 
suggests that there are multiple EDHFs, and that the chemical mediators of the 
EDHF response may vary with the vascular bed (Edwards & Weston, 1998; 
McGuire et al., 2001). In recent years, the most popular candidates for EDHF have 
been the non-prostanoid products of the metabolism of arachidonic acid, namely 
epoxyeicosatrienoic acids (Campbell et al., 2003; Archer et al., 2003; Gauthier et al., 
2005). EDHF has been reported to be diffusible factor, which causes the opening of 
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K+ channels in the smooth muscle membrane (Quilley et al., 1997; Edwards & 
Weston, 1998; McGuire et al., 2001; Triggle et al., 2003). Involvement of adenosine 
5’-triphosphate (ATP)-sensitive K+ channels (KATP) and Na+/ K+-ATPase has been 
reported in some vessels, but in the majority of the studies EDHF has been 
suggested to act through Ca2+ activated K+ channels (McGuire et al., 2001). The 
action of EDHF can be inhibited by K+ channel blockers or by depolarizing the 
smooth muscle with increasing extra cellular high K+ concentrations (Adeagbo et al., 
1993; Ueda et al., 2005). 
 
The release of EDHF is as similar as that of NO and PGI2 which is initiated by 
an increase in intracellular free Ca2+ concentration in the endothelial cell (Cohen & 
Vanhoutte, 1995; Luscher & Noll, 1995). Consequently, many autocoids and 
hormones that release NO and PGI2 have also been shown to release EDHF (Cohen 
& Vanhoutte 1995). The mechanisms whereby hyperpolarization causes relaxation 
remain controversial (Triggle et al., 2003). Most likely, the hyperpolarization of the 
smooth muscle cell membrane reduces Ca2+ influx through voltage dependent Ca2+ 
channels, which allows the Ca2+ sequestration and removal of lower intracellular 
free Ca2+ concentration. The importance of EDHF in endothelium-dependent 
relaxations has been reported to increase as the artery size decreases (McGuire et al., 
2001; Triggle et al., 2003). It is also suggested that EDHF-mediated relaxation is 
upregulated in the pathophysiological states, such as hypertension and diabetes, 
which are associated with reduced bioavailability of NO (Ding et al., 2000; McGuire 
et al., 2001; Endemann & Schiffrin, 2004). Decreased endothelium-mediated 
hyperpolarization has been observed in many forms of experimental hypertension 
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and diabetes (McGuire et al., 2001; Triggle et al., 2003; Endemann & Schiffrin, 
2004). 
 
  Hydrogen sulphide (H2S) is increasingly being recognized as an important 
signalling molecule in the cardiovascular and nervous systems (Csaba Szabó (2007). 
The production of H2S from L-cysteine is catalysed primarily by two enzymes, 
cystathionine γ-lyase and cystathionine β-synthase. Evidence is accumulating to 
demonstrate that inhibitors of H2S production or therapeutic H2S donor compounds 
exert significant effects in various animal models of inflammation, reperfusion 
injury and circulatory shock. H2S can also induce a reversible state of hypothermia 
and suspended-animation-like state in rodents (Csaba Szabó (2007). Intravenous 
bolus injection of H2S transiently decreased the blood pressure of the rats by 12 ± 30 
mmHg which was antagonized by prior blockade of KATP channels (Zhao et al., 
2001). H2S also relaxed rat aortic tissues in vitro in a KATP channels-dependent 
manner (Zhao et al., 2001).  
 
   Over the last decade, studies have unraveled many aspects of endogenous 
production and physiological functions of carbon monoxide (CO). The majority of 
endogenous CO is produced in a reaction catalyzed by the enzyme heme oxygenase 
(HO). Inducible HO (HO-1) and constitutive HO (HO-2) are mostly recognized for 
their roles in the oxidation of heme and production of CO and biliverdin, whereas 
the biological function of the third HO isoform, HO-3, is still unclear (Wu & Wang, 
2005). The interaction of CO and ion channels constitutes an important mechanism 
for the biological effect of CO. Most noticeable among the CO-targeted ion channels 
are K+ channels. This superfamily is composed of voltage- dependent Kv, ATP-
 18
sensitive KATP, and calcium activated KCa channels (Wu & Wang, 2005). The 
interaction of CO and K+ channels may be the dominant force in driving the CO-
induced vasorelaxation in specific types of blood vessels, especially peripheral 
resistance and cerebral arterioles. In other types of blood vessels, CO effects on K+ 
channels may become less important compared with activation of the cGMP 
pathway by CO (Wu & Wang, 2005). 
 
  Barkoudah et al. (2004) recently showed that application of a CO-releasing 
compound dilated arteriolar branches of the middle cerebral artery from piglets by 
activating BKCa channels in vascular smooth muscle cells. However, removal of 
endothelium or blocking the sGC-cGMP pathway abolished CO-induced 
vasorelaxation. Release of NO from endothelium or activation of sGC-cGMP 
pathway in vascular SMC allowed CO to cause vascular dilation (Wu & Wang, 
2005). 
 
1.7 Hypertension 
Hypertension is one of the leading causes of cardiovascular and 
cerebrovascular complications, the most common reason to visit physician offices, 
and number one reason for drug prescriptions all over the world (Kearney et al., 
2005). Hypertension is characterized by a normal cardiac output and elevated arterial 
pressure. The etiology of hypertension is multifactorial and the precise mechanisms 
are not completely understood. Hypertension is a consequence of the interaction 
between genetics and the internal environment of the body. 
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Two forms of hypertension have been described: 
1. Primary or essential hypertension 
2. Secondary hypertension 
 
Essential hypertension is a far more common condition and accounts for 95% 
of all cases of hypertension whereas secondary hypertension accounts for only 5%. 
Endothelial dysfunction and vascular smooth muscle dysfunction are initiating and 
perpetuating factors in essential hypertension (Luscher & Noll, 1990; Amudha et al., 
2002; Endemann & Schiffrin, 2004). In hypertension, the cardiovascular system 
exhibits several important physiological and morphological changes, chief among 
which are increase in the blood pressure, cardiac hypertrophy (increased cardiac 
muscle mass of blood vessels), impairment in vascular contraction and relaxation 
(Taddie et al., 1998; Ludwig et al., 2002; Sabbatini et al., 2002; Endeman & 
Schiffrin, 2004). However, inspite of several studies on animal models of 
hypertension as well as in hypertensive human subjects, the exact mechanisms 
responsible for these pathological changes remain uncertain. It is suggested that the 
narrowing of the blood vessels contributed to increased peripheral vascular 
resistance and consequently to elevated blood pressure. This view is supported by 
the regression observed in the abnormal structure of blood vessels in hypertension 
towards physiological value with antihypertensive treatments (Ludwig et al., 2002; 
Sabbatini et al., 2002). 
 
In recent past, the pharmacological research is focused on multidisciplinary 
drug discovery aaproach on isolation, synthesis and evaluation of emerging 
vasodilating drug molecules with maximum therapeutic effect with minimum or no 
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side effects. The plants which can enhance the NO-cGMP pathway and a direct 
action on the vascular smooth muscle through a dephosphorylation of myosin light 
chain kinase, resulting in vasodilation. 
 
1.8 Some pharmacologically active moieties from natural flora used in 
cardiovascular malfunctions 
Several coumarin derivatives have been shown to possess cardiovascular 
properties. Many of them are selective coronary vasodilators, an effect that may be 
related to a Ca2+-antagonistic activity. Carbochromen (3-diethylaminoethyl-7-
ethoxycarbonylmethoxy-4-methylcoumarin) is a potent specific coronary vasodilator 
which has been used for many years in the treatment of angina pectoris. Although 
the exact mechanism of action remains still unknown, it has been reported that 
carbochromen coronary effects could be mediated by an increased release of 
prostaglandins. Khellin (2-methyl-5, 8-dimethoxyfurochromone) is an active 
principle obtained from Ammi visnaga L. has strong vasodilator and spasmolytic 
activities. It probably decreases the availability of Ca2+ required for smooth muscle 
activation acting at multiple sites (Toimil et al., 2002). 
 
Vasorelaxing activity of the aqueous extract of Caesalpinia benthamiana 
(AECB) roots was tested using isolated rat aortic rings precontracted by 
phenylephrine (PE). Interaction of AECB with NO generation was also investigated 
by quantitative polymerase chain reaction (QPCR) analysis and its antioxidant 
properties were assessed by using human polymorphonuclear neutrophils (PMNs) in 
a cellular pathophysiological model of oxidative burst. Scavenging activities versus 
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superoxide anion (O2−), hydrogen peroxide (H2O2), and hypochlorous acid (HOCl) 
were evaluated in the cell-free system (Alexis et al., 2008).  
 
The in vitro and ex vivo suppressive effects of Andrographis paniculata on 
nitric oxide production in mouse peritoneal macrophages is elicited by Bacillus 
Calmette-Guein (BCG) and stimulated by lipopolysaccharide (LPS). Incubation of 
BCG-induced macrophages with the methanol extract of A. paniculata reduced LPS 
stimulated NO production. The diterpene lactones andrographolide and 
neoandrographolide were isolated as active components from the extract. These 
compounds suppressed NO production in a concentration-dependent manner in the 
concentration range from 0.1 to 100 µM and their IC50 values were 7.9 and 35.5 µM. 
Neoandrographolide at doses of 5 and 25 mg/kg/day suppressed NO production by 
35% and 40%. However, andrographolide did not reduce NO production on oral 
administration at the same doses. These results indicate that neoandrographolide, 
which inhibited NO production both in vitro and ex vivo may play an important role 
in the use of A. paniculata as an anti-inflammatory crude drug (Javzan et al., 2002). 
 
1.9. Conventional antihypertensive agents 
 Antihypertensive agents act at one or more of the four anatomic control sites 
and produce their effects by interfering with normal mechanisms of blood pressure 
regulation. A useful classification of these agents categorizes them according to the 
principal regulatory site or mechanism on which they act (Chobanian et al., 2003). 
1) Diuretics, which lowers blood pressure by depleting the body sodium ion 
concentration and reducing blood volume and by other mechanisms 
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Four basic types of diuretics are used in treatment of hypertension. 
a)  Thiazide diuretics: Hydrochlorthiazide, chlorthiazide, indapamide etc  
 b)  High ceiling diuretics: Furosemide, bumetanide, ethacrynic acid 
 c)  Aldosterone antagonist: Spironolactone  
 d)  Angiotensin II receptor: Losartan, irbesartan, valsartan, telmisartan. 
2)  Drugs modifying sympathetic nervous system activity 
 a) Centrally acting drugs: Clonidine and methyldopa are believed to act upon 
vasomotor centers in the brain to decrease peripheral sympathetic nervous system 
tone. The drugs decrease cardiac output and peripheral resistance. 
 
 b) Inhibitors of neurotransmitter release and/or storage, guanethidine are 
actively transported into adrenergic nerve endings and inhibit norepinephrine release 
with nerve stimulation. Nerve uptake is necessary for the drug’s antihypertensive 
actions. 
 c) Adrenergic receptor blockers 
 i) α-adrenergic receptor antagonists: Prazosin, doxazosin, terazosin  
Prazosin’s antihypertensive actions are mentioned via competitive blockade of α1-
receptor in peripheral arterioles, reducing vascular resistance. Prazocin is selective 
α1-receptor blocker its first dose produce severe hypotension. 
 
ii) β-adrenergic receptor antagonist: Propranolol, acebutolol, atenolol,     
metoprolol  
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β-adrenergic receptor antagonists reduce blood pressure by reducing heart rate and 
myocardial contractility (reduced cardiac output). These are considered as effective 
agents for mild to moderate hypertension.  
 
3) Combination alpha/beta adrenergic receptor blockers: Labetalol, trandate 
Labetalol exhibits both selective α1-adrenoceptor blockade and non-selective β-
adrenoceptor blockade. The antihypertensive action of the drugs is results from a 
decrease in peripheral resistance with little or no decrease on cardiac out put. The 
drug is most useful for the treatment of mild to moderate hypertension. 
 
3) Vasodilators 
a) Direct vasodilators: Hydralazine, minoxidil, diazoxide, sodium 
nitroprusside 
Direct vasodilators act upon vascular smooth muscle to produce a relaxation of 
vascular tone and a decrease in peripheral resistance. 
 b) Calcium entry blockers: Isradipine, nifedipine, diltiazem, amlodipine,  
     felodipine, lercanidipine and verapamil hydrochloride. 
The calcium entry blockers inhibit calcium entry into myocardial and vascular 
smooth muscle cells. The drugs can decrease peripheral resistance and decrease 
cardiac output the relative sensitivity of vascular smooth muscle and cardiac tissue 
vary with the three prototype agents. They are used for treatment of mild or 
moderate hypertension. 
 
4) Angiotensin converting enzyme inhibitors (ACE Inhibitors): Captorpil, esinopril, 
ramipril, perindopril.   
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CHAPTER 2 
REVIEW OF LITERATURE 
 
2.0 Andrographis paniculata 
Malaysia is a known as one of the 12 mega-diversity centre harbouring a 
multitude of medicinal plant species each presumably studded with as yet unknown 
genetic and chemical variations of economic importance. Several medicinal plants 
occurring in Malaysia species are used over several centuries in the traditional 
systems of medicine. Nearly 75% of the herbal drugs and perfumery products used 
in the world are available in natural state. Therefore, the rich and varied plant 
diversity, especially the genetic diversity of medicinal and aromatic plants, is one of 
country important strengths and is the bedrock for all future bio-industrial 
developments. Unfortunately, the renowned medicinal plant wealth of Malaysia has 
seldom been subjected to genetic scrutiny keeping in mind the latent and patentable 
properties and economic utility of the selected plant types. As severe habitat losses 
and consequent endangerment and extinction of known and hitherto lesser known 
species of economic value are not uncommon in this country, it is imperative that 
heritable variations within the otherwise unimproved natural populations of 
prospective taxa are studied for selection, improvement and development of suitable 
cultivars. Otherwise called bio-prospecting, this line of research is essential to fish 
out useful genes and gene products for commercialisation in the now unfolded patent 
regime. Knowledge of the genetic diversity is also a prerequisite for any in situ and 
ex situ conservation schemes (Hamrick et al., 1991) as it is not practical to conserve 
all genotypes of a given species against the mass extinction spasm projected for the 
21st century (Raven, 1999). 
